Cargando…

First participant diagnosed with Creutzfeldt-Jakob disease in the population-based Rotterdam Study was classified with mild cognitive impairment

Sporadic Creutzfeldt-Jakob disease (sCJD) is a rare, fatal, neurodegenerative disease caused by accumulation of abnormally folded prion protein. sCJD can have a long asymptomatic incubation period, with little known about this period. We describe the first-ever participant within the population-base...

Descripción completa

Detalles Bibliográficos
Autores principales: Karamujić-Čomić, Hata, Rozemuller, Annemieke J M, Ikram, M Arfan, van Duijn, Cornelia M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009210/
https://www.ncbi.nlm.nih.gov/pubmed/33782059
http://dx.doi.org/10.1136/bcr-2020-235509
_version_ 1783672835848273920
author Karamujić-Čomić, Hata
Rozemuller, Annemieke J M
Ikram, M Arfan
van Duijn, Cornelia M
author_facet Karamujić-Čomić, Hata
Rozemuller, Annemieke J M
Ikram, M Arfan
van Duijn, Cornelia M
author_sort Karamujić-Čomić, Hata
collection PubMed
description Sporadic Creutzfeldt-Jakob disease (sCJD) is a rare, fatal, neurodegenerative disease caused by accumulation of abnormally folded prion protein. sCJD can have a long asymptomatic incubation period, with little known about this period. We describe the first-ever participant within the population-based Rotterdam Study diagnosed with sCJD. We retrieved clinical data from both the population-based Rotterdam Study and the National Prion Disease Registry. In 2011, a female participant of the Rotterdam Study was diagnosed with probable sCJD and registered into the Registry. Four months earlier, she was classified as having mild cognitive impairment based on assessment in the Rotterdam Study. Clinical deterioration was rapid, with the patient dying 7 months after the research centre visit. Postmortem brain autopsy confirmed the diagnosis of sCJD. In conclusion, we describe the first case diagnosed with sCJD who during diagnostic workup for sCJD was classified as having mild cognitive impairment in a population-based cohort study.
format Online
Article
Text
id pubmed-8009210
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-80092102021-04-16 First participant diagnosed with Creutzfeldt-Jakob disease in the population-based Rotterdam Study was classified with mild cognitive impairment Karamujić-Čomić, Hata Rozemuller, Annemieke J M Ikram, M Arfan van Duijn, Cornelia M BMJ Case Rep Case Report Sporadic Creutzfeldt-Jakob disease (sCJD) is a rare, fatal, neurodegenerative disease caused by accumulation of abnormally folded prion protein. sCJD can have a long asymptomatic incubation period, with little known about this period. We describe the first-ever participant within the population-based Rotterdam Study diagnosed with sCJD. We retrieved clinical data from both the population-based Rotterdam Study and the National Prion Disease Registry. In 2011, a female participant of the Rotterdam Study was diagnosed with probable sCJD and registered into the Registry. Four months earlier, she was classified as having mild cognitive impairment based on assessment in the Rotterdam Study. Clinical deterioration was rapid, with the patient dying 7 months after the research centre visit. Postmortem brain autopsy confirmed the diagnosis of sCJD. In conclusion, we describe the first case diagnosed with sCJD who during diagnostic workup for sCJD was classified as having mild cognitive impairment in a population-based cohort study. BMJ Publishing Group 2021-03-29 /pmc/articles/PMC8009210/ /pubmed/33782059 http://dx.doi.org/10.1136/bcr-2020-235509 Text en © BMJ Publishing Group Limited 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Case Report
Karamujić-Čomić, Hata
Rozemuller, Annemieke J M
Ikram, M Arfan
van Duijn, Cornelia M
First participant diagnosed with Creutzfeldt-Jakob disease in the population-based Rotterdam Study was classified with mild cognitive impairment
title First participant diagnosed with Creutzfeldt-Jakob disease in the population-based Rotterdam Study was classified with mild cognitive impairment
title_full First participant diagnosed with Creutzfeldt-Jakob disease in the population-based Rotterdam Study was classified with mild cognitive impairment
title_fullStr First participant diagnosed with Creutzfeldt-Jakob disease in the population-based Rotterdam Study was classified with mild cognitive impairment
title_full_unstemmed First participant diagnosed with Creutzfeldt-Jakob disease in the population-based Rotterdam Study was classified with mild cognitive impairment
title_short First participant diagnosed with Creutzfeldt-Jakob disease in the population-based Rotterdam Study was classified with mild cognitive impairment
title_sort first participant diagnosed with creutzfeldt-jakob disease in the population-based rotterdam study was classified with mild cognitive impairment
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009210/
https://www.ncbi.nlm.nih.gov/pubmed/33782059
http://dx.doi.org/10.1136/bcr-2020-235509
work_keys_str_mv AT karamujiccomichata firstparticipantdiagnosedwithcreutzfeldtjakobdiseaseinthepopulationbasedrotterdamstudywasclassifiedwithmildcognitiveimpairment
AT rozemullerannemiekejm firstparticipantdiagnosedwithcreutzfeldtjakobdiseaseinthepopulationbasedrotterdamstudywasclassifiedwithmildcognitiveimpairment
AT ikrammarfan firstparticipantdiagnosedwithcreutzfeldtjakobdiseaseinthepopulationbasedrotterdamstudywasclassifiedwithmildcognitiveimpairment
AT vanduijncorneliam firstparticipantdiagnosedwithcreutzfeldtjakobdiseaseinthepopulationbasedrotterdamstudywasclassifiedwithmildcognitiveimpairment